STXBP5

Across TCGA pan-cancer cohorts, STXBP5 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of STXBP5’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where STXBP5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types STXBP5 is over-expressed in tumor, although a few such as COAD and KICH show the opposite, repressed pattern.

LIHC, CHOL, and COAD are the cancer types where STXBP5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STXBP5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.676	<.001	6	view →
CHOL	All	All	+1.991	<.001	5	view →
COAD	Female	All	−0.635	.005	4	view →
KICH	Female	All	−0.711	<.001	3	view →
READ	All	All	−0.708	<.001	2	view →
BRCA	All	III,IV	−0.350	.038	2	view →
THCA	All	II,III,IV	−0.312	.023	2	view →
LUAD	All	All	+0.305	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

STXBP5–LIHC

Open the LIHC breakdown →